YZYBIO-B Receives NMPA Acceptance for M701 New Drug Application Targeting Malignant Ascites

Stock News

05/07

YZYBIO-B (02496) has announced that the New Drug Application for its self-developed bispecific antibody drug M701, intended for the treatment of malignant ascites caused by advanced epithelial malignancies, has been formally accepted by the National Medical Products Administration. This acceptance is based on findings from a Phase III clinical trial conducted in China, which evaluated the efficacy and safety of intraperitoneal infusion of M701 in patients with advanced epithelial tumors presenting moderate to large amounts of malignant ascites. The relevant research data is scheduled to be presented at the 2026 American Society of Clinical Oncology annual meeting.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1181865718"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1181865718\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1181865718?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 17:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181865718","market":"sg","top_or_hot":-1,"title":"YZYBIO-B Receives NMPA Acceptance for M701 New Drug Application Targeting Malignant Ascites","media":"Stock News","content":"<p>YZYBIO-B (02496) has announced that the New Drug Application for its self-developed bispecific antibody drug M701, intended for the treatment of malignant ascites caused by advanced epithelial malignancies, has been formally accepted by the National Medical Products Administration. This acceptance is based on findings from a Phase III clinical trial conducted in China, which evaluated the efficacy and safety of intraperitoneal infusion of M701 in patients with advanced epithelial tumors presenting moderate to large amounts of malignant ascites. The relevant research data is scheduled to be presented at the 2026 American Society of Clinical Oncology annual meeting.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>YZYBIO-B Receives NMPA Acceptance for M701 New Drug Application Targeting Malignant Ascites</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYZYBIO-B Receives NMPA Acceptance for M701 New Drug Application Targeting Malignant Ascites\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-05-07 17:38</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>YZYBIO-B (02496) has announced that the New Drug Application for its self-developed bispecific antibody drug M701, intended for the treatment of malignant ascites caused by advanced epithelial malignancies, has been formally accepted by the National Medical Products Administration. This acceptance is based on findings from a Phase III clinical trial conducted in China, which evaluated the efficacy and safety of intraperitoneal infusion of M701 in patients with advanced epithelial tumors presenting moderate to large amounts of malignant ascites. The relevant research data is scheduled to be presented at the 2026 American Society of Clinical Oncology annual meeting.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1181865718","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181865718","pubTimestamp":1778146700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"YZYBIO-B (02496) has announced that the New Drug Application for its self-developed bispecific antibody drug M701, intended for the treatment of malignant ascites caused by advanced epithelial...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","IPOS":"Renaissance International IPO ETF","02496":"友芝友生物-B"},"translate_title":"友济生物-B获NMPA受理M701靶向恶性腹水新药申请","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02496":1,"IPOS":1},"content_text":"YZYBIO-B (02496) has announced that the New Drug Application for its self-developed bispecific antibody drug M701, intended for the treatment of malignant ascites caused by advanced epithelial malignancies, has been formally accepted by the National Medical Products Administration. This acceptance is based on findings from a Phase III clinical trial conducted in China, which evaluated the efficacy and safety of intraperitoneal infusion of M701 in patients with advanced epithelial tumors presenting moderate to large amounts of malignant ascites. The relevant research data is scheduled to be presented at the 2026 American Society of Clinical Oncology annual meeting.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}